Abstract
Trimethylamine-N-oxide (TMAO) is a low molecular weight metabolite whose production is dependent on metabolism of its precursors choline, carnitine, creatinine, betaine or lecithin by host gut microbes resulting in the synthesis of trimethylamine (TMA), which is subsequently oxidized to TMAO via hepatic flavin monooxygenase (FMO). TMAO is associated with microbial dysbiosis and is being studied for its linkage with cardiovascular disorders. In addition, dysregulated levels of TMAO have been linked with renal diseases, neurological disorders and cancer. Here we discuss the enzymatic and metabolic landscape that results in TMAO production, and in addition, collate data from numerous clinical studies that have assessed TMAO as a biomarker for various disease conditions. We also summarize the interaction of TMAO with modern and traditional drugs that together affect circulating TMAO levels in the human body.
Keywords: Antibiotic resistance, cardio-metabolic disorders, diet, herbs, metabolite, trimethylamine-N-oxide.
Current Medicinal Chemistry
Title:The Metabolite Trimethylamine-N-Oxide is an Emergent Biomarker of Human Health
Volume: 24 Issue: 36
Author(s): Jyoti Chhibber-Goel*, Varsha Singhal, Neeraj Parakh, Balram Bhargava and Amit Sharma*
Affiliation:
- Molecular Medicine Group, International Centre for Genetic Engineering and Biotechnology, New Delhi,India
- Molecular Medicine Group, International Centre for Genetic Engineering and Biotechnology, New Delhi,India
Keywords: Antibiotic resistance, cardio-metabolic disorders, diet, herbs, metabolite, trimethylamine-N-oxide.
Abstract: Trimethylamine-N-oxide (TMAO) is a low molecular weight metabolite whose production is dependent on metabolism of its precursors choline, carnitine, creatinine, betaine or lecithin by host gut microbes resulting in the synthesis of trimethylamine (TMA), which is subsequently oxidized to TMAO via hepatic flavin monooxygenase (FMO). TMAO is associated with microbial dysbiosis and is being studied for its linkage with cardiovascular disorders. In addition, dysregulated levels of TMAO have been linked with renal diseases, neurological disorders and cancer. Here we discuss the enzymatic and metabolic landscape that results in TMAO production, and in addition, collate data from numerous clinical studies that have assessed TMAO as a biomarker for various disease conditions. We also summarize the interaction of TMAO with modern and traditional drugs that together affect circulating TMAO levels in the human body.
Export Options
About this article
Cite this article as:
Chhibber-Goel Jyoti*, Singhal Varsha, Parakh Neeraj, Bhargava Balram and Sharma Amit*, The Metabolite Trimethylamine-N-Oxide is an Emergent Biomarker of Human Health, Current Medicinal Chemistry 2017; 24(36) . https://dx.doi.org/10.2174/0929867323666160830104025
DOI https://dx.doi.org/10.2174/0929867323666160830104025 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Biphasic Mechanisms of Neurovascular Unit Injury and Protection in CNS Diseases
CNS & Neurological Disorders - Drug Targets Inhibition of Inflammation by a p38 MAP Kinase Targeted Cell Permeable Peptide
Medicinal Chemistry Endothelial Progenitor Cells in Prehypertension
Current Pharmaceutical Design Selenium Compounds Biotransformed by Mushrooms: Not Only Dietary Sources, But Also Toxicity Mediators
Current Nutrition & Food Science Tumoricidal and Anti-Angiogenic Actions of Gamma-Linolenic Acid and Its Derivatives
Current Pharmaceutical Biotechnology Clinical Applications of Nanotechnology in Atherosclerotic Diseases
Current Nanoscience Kinase Inhibitor Conjugates
Current Pharmaceutical Design Structure and Function of Poly(ADP-ribose) Polymerase-1: Role in Oxidative Stress-Related Pathologies
Current Vascular Pharmacology The Role of the Endothelium in Premature Atherosclerosis: Molecular Mechanisms
Current Medicinal Chemistry The Molecular Basis of Memantine Action in Alzheimers Disease and Other Neurologic Disorders: Low-affinity, Uncompetitive Antagonism
Current Alzheimer Research Human Ghrelin: A Gastric Hormone with Cardiovascular Properties
Current Pharmaceutical Design Use of Clinically Available PPAR Agonists for Heart Failure; Do the Risks Outweigh the Potential Benefits?
Current Molecular Pharmacology Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors
Current Pharmaceutical Design Matrix Metalloproteinases and their Tissue Inhibitors in Diabetes, Atherosclerosis and Prediction of the Cardiovascular Risk
Current Enzyme Inhibition Peptide Metabolism and the Control of Body Fluid Homeostasis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Signal Transduction Pathways of Inflammatory Gene Expressions and Therapeutic Implications
Current Pharmaceutical Design The Potential of p38 MAPK Inhibitors to Modulate Periodontal Infections
Current Drug Metabolism Design, Synthesis, and Evaluation of Heat Shock Protein 90 Inhibitors in Human Breast Cancer and Its Metastasis
Current Pharmaceutical Biotechnology Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson's Disease
Current Stem Cell Research & Therapy Monitoring Inflammation, Humoral and Cell-mediated Immunity in Pancreas and Islet Transplants
Current Diabetes Reviews